The estimated Net Worth of Xiaochun Boyalife Group, In... is at least $677 mil dollars as of 17 November 2023. Xiaochun In owns over 600,000 units of ThermoGenesis Inc stock worth over $65,424 and over the last few years Xiaochun sold THMO stock worth over $612,000.
Xiaochun has made over 1 trades of the ThermoGenesis Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Xiaochun sold 600,000 units of THMO stock worth $612,000 on 17 November 2023.
The largest trade Xiaochun's ever made was selling 600,000 units of ThermoGenesis Inc stock on 17 November 2023 worth over $612,000. On average, Xiaochun trades about 150,000 units every 0 days since 2023. As of 17 November 2023 Xiaochun still owns at least 327,121 units of ThermoGenesis Inc stock.
You can see the complete history of Xiaochun In stock trades at the bottom of the page.
Xiaochun's mailing address filed with the SEC is 2711 CITRUS ROAD2453 S. ARCHER AVE., SUITE B, RANCHO CORDOVACHICAGO, CAIL, 9574260616.
Over the last 5 years, insiders at ThermoGenesis Inc have traded over $612,000 worth of ThermoGenesis Inc stock. The most active insiders traders include Xiaochun Boyalife Group, In... y Thomis Joseph. On average, ThermoGenesis Inc executives and independent directors trade stock every 0 days with the average trade being worth of $120,000. The most recent stock trade was executed by Xiaochun Boyalife Group, In... on 17 November 2023, trading 600,000 units of THMO stock currently worth $612,000.
thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli
ThermoGenesis Inc executives and other stock owners filed with the SEC include: